<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006400</url>
  </required_header>
  <id_info>
    <org_study_id>89</org_study_id>
    <secondary_id>N01 HB07150</secondary_id>
    <secondary_id>N01 HB07151</secondary_id>
    <secondary_id>N01 HB07152</secondary_id>
    <secondary_id>N01 HB07153</secondary_id>
    <secondary_id>N01 HB07154</secondary_id>
    <secondary_id>N01 HB07155</secondary_id>
    <secondary_id>N01 HB07156</secondary_id>
    <secondary_id>N01 HB07157</secondary_id>
    <secondary_id>N01 HB07158</secondary_id>
    <secondary_id>N01 HB07159</secondary_id>
    <secondary_id>N01 HB07160</secondary_id>
    <nct_id>NCT00006400</nct_id>
  </id_info>
  <brief_title>Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia</brief_title>
  <official_title>Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if hydroxyurea therapy is effective in the&#xD;
      prevention of chronic end organ damage in pediatric patients with sickle cell anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      In 1995, the Multicenter Study of Hydroxyurea (MSH) demonstrated that hydroxyurea is&#xD;
      effective in decreasing the frequency of painful crises, hospitalizations for crises, acute&#xD;
      chest syndrome, and blood transfusions by 50%. The recently completed phase II study of&#xD;
      hydroxyurea in children (PED HUG) demonstrated that children have a response to hydroxyurea&#xD;
      similar to that seen in adults in terms of increasing fetal hemoglobin levels and total&#xD;
      hemoglobin, and decreasing complications associated with sickle cell anemia. In addition,&#xD;
      this study demonstrated that the drug does not adversely affect growth and development&#xD;
      between the ages of 5 and 15. A recently completed pilot study of hydroxyurea given to&#xD;
      children between the ages of 6 months and 24 months demonstrated that the drug is tolerated&#xD;
      well by small infant, and that the fetal hemoglobin switch can be forced to remain in the &quot;on&#xD;
      position&quot; by hydroxyurea administration.&#xD;
&#xD;
      A Special Emphasis Panel (SEP) met on April 12, 1996 to review the results of the MSH trial&#xD;
      and the progress to date of the PED HUG study. The SEP recommended that NHLBI undertake the&#xD;
      BABY HUG trial.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      BABY HUG is a randomized, double-blind, placebo-controlled study to determine if hydroxyurea&#xD;
      can prevent the onset of chronic end organ damage in young children with sickle cell anemia.&#xD;
      Approximately 200 children with sickle cell disease will be recruited to receive either&#xD;
      hydroxyurea or placebo. The children will be screened at study entry for signs of abnormal&#xD;
      brain, kidney, pulmonary, and splenic function, and developmental milestones. They will then&#xD;
      be randomly assigned to receive either hydroxyurea or placebo and followed yearly to assess&#xD;
      chronic end organ damage of the major organ systems. The primary endpoint will be a 50%&#xD;
      reduction in rates of damage to the major organs with surrogate markers of organ function&#xD;
      during follow-up in Phase II of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Differences of the Change in Qualitative Splenic Function From Baseline</measure>
    <time_frame>Before initiation of treatment and at 2 years</time_frame>
    <description>Primary Endpoint: Spleen function was assessed by uptake of 99mTc sulfur colloid on liver-spleen scan before initiation of treatment (baseline) and 2 years later (exit). The results of each of the two scans were categorized as normal, functional but abnormal, or not functional by a panel of nuclear medicine specialists blinded to treatment assignment. The proportion of patients whose paired scans demonstrated a decline in splenic function was compared in the hydroxyurea versus placebo groups.&#xD;
The change in splenic function from baseline to 2 years was defined as worse if it changed from normal to decreased or absent, or decreased to absent; and not worse if it changed from decreased to decreased, normal to normal, or decreased to normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Before initiation of treatment and at 2 years</time_frame>
    <description>DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)</measure>
    <time_frame>Before initiation of treatment and at 2 years</time_frame>
    <description>Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)</measure>
    <time_frame>Before initiation of treatment and at 2 years</time_frame>
    <description>GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive hydroxyurea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Participants will receive hydroxyurea.</description>
    <arm_group_label>Hydroxyurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Majority fetal and sickle (FS or SF) hemoglobin pattern confirmed centrally by&#xD;
             electrophoresis (screening may begin at 7 months of age)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic transfusion therapy&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Less than 5th percentile (10th percentile for the pilot study) height, weight, or head&#xD;
             circumference for age&#xD;
&#xD;
          -  Severe developmental delay (e.g., cerebral palsy or other mental retardation, Grade&#xD;
             III/IV intraventricular hemorrhage)&#xD;
&#xD;
          -  Stroke with neurological deficit&#xD;
&#xD;
          -  Surgical splenectomy&#xD;
&#xD;
          -  Participating in other clinical intervention trials&#xD;
&#xD;
          -  Probable or known diagnosis of Hemoglobin S-Hereditary Persistence of Fetal Hemoglobin&#xD;
&#xD;
          -  Known hemoglobin S-beta plus thalassemia (hemoglobin A present)&#xD;
&#xD;
          -  Any condition or chronic illness, which in the opinion of the principal investigator,&#xD;
             makes participation unadvised or unsafe&#xD;
&#xD;
          -  Inability or unwillingness to complete baseline (pre-enrollment) studies, including&#xD;
             blood or urine specimen collection, liver-spleen scan, abdominal sonogram,&#xD;
             neurological examination, neuropsychological testing, or transcranial Doppler&#xD;
             ultrasound (interpretable study not required, but confirmed velocity greater than 200&#xD;
             cm/sec results in ineligibility)&#xD;
&#xD;
          -  Previous or current treatment with hydroxyurea (HU) or another anti-sickling drug&#xD;
&#xD;
          -  The following exclusion criteria are transient; patients can be re-evaluated for&#xD;
             eligibility:&#xD;
&#xD;
               1. Hemoglobin less than 6.0 gm/dL&#xD;
&#xD;
               2. Reticulocyte count less than 80,000/cu mm if hemoglobin is less than 9 gm/dL&#xD;
&#xD;
               3. Neutrophil count less than 2,000/cu mm&#xD;
&#xD;
               4. Platelet count less than 130,000/cu mm&#xD;
&#xD;
               5. Blood transfusion in the 2 months prior to study entry unless HbA is less than&#xD;
                  10%&#xD;
&#xD;
               6. ALT greater than twice the upper limit of normal&#xD;
&#xD;
               7. Ferritin less than 10 ng/ml&#xD;
&#xD;
               8. Serum creatinine greater than twice the upper limit of normal for age&#xD;
&#xD;
               9. Bayley standardized mental score below 70&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherron Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James F. Casella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori Luchtman-Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rathi V. Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott T. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Health Science Center, Brooklyn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sohail R. Rana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zora R. Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas SW Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce W Thompson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials and Surveys Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Barredo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winfred C. Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Courtney Thornburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Howard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori Luck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Clark Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharada Sarnaik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan/Wayne State Univ.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Health Science Center, Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas SW Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol. 2004 Mar;26(3):179-84. doi: 10.1097/00043426-200403000-00007.</citation>
    <PMID>15125610</PMID>
  </reference>
  <reference>
    <citation>Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer. 2010 Feb;54(2):250-5. doi: 10.1002/pbc.22269.</citation>
    <PMID>19731330</PMID>
  </reference>
  <results_reference>
    <citation>Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.</citation>
    <PMID>21571150</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang WC, Pavlakis SG, Helton KJ, McKinstry RC, Casella JF, Adams RJ, Rees RC; BABY HUG Investigators. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer. 2008 Nov;51(5):643-6. doi: 10.1002/pbc.21612. Erratum In: Pediatr Blood Cancer. 2020 May;67(5):e28238.</citation>
    <PMID>18478575</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller ST, Wang WC, Iyer R, Rana S, Lane P, Ware RE, Li D, Rees RC; BABY-HUG Investigators. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer. 2010 Feb;54(2):265-8. doi: 10.1002/pbc.22189.</citation>
    <PMID>19621454</PMID>
  </results_reference>
  <results_reference>
    <citation>Pavlakis SG, Rees RC, Huang X, Brown RC, Casella JF, Iyer RV, Kalpatthi R, Luden J, Miller ST, Rogers ZR, Thornburg CD, Wang WC, Adams RJ; BABY HUG Investigators. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer. 2010 Feb;54(2):256-9. doi: 10.1002/pbc.22282.</citation>
    <PMID>19813252</PMID>
  </results_reference>
  <results_reference>
    <citation>Thornburg CD, Rogers ZR, Jeng MR, Rana SR, Iyer RV, Faughnan L, Hassen L, Marshall J, McDonald RP, Wang WC, Huang X, Rees RC; BABY HUG Investigators. Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer. 2010 Feb;54(2):260-4. doi: 10.1002/pbc.22324.</citation>
    <PMID>19856395</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shalaby-Rana E, Strife CF, Miller JH, Lane PA, Wang WC, Miller ST; BABY HUG Investigators. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010 Jan;156(1):66-70.e1. doi: 10.1016/j.jpeds.2009.06.060.</citation>
    <PMID>19880138</PMID>
  </results_reference>
  <results_reference>
    <citation>Wynn L, Miller S, Faughnan L, Luo Z, Debenham E, Adix L, Fish B, Hustace T, Kelly T, Macdermott M, Marasciulo J, Martin B, McDuffie J, Murphy M, Rackoff B, Reed C, Seaman P, Thomas G, Wang W. Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study. Contemp Clin Trials. 2010 Nov;31(6):558-63. doi: 10.1016/j.cct.2010.08.007. Epub 2010 Aug 24.</citation>
    <PMID>20797449</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE; BABY HUG. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood. 2011 Mar 3;117(9):2614-7. doi: 10.1182/blood-2010-04-278747. Epub 2011 Jan 7.</citation>
    <PMID>21217080</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>October 12, 2000</study_first_submitted>
  <study_first_submitted_qc>October 12, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2000</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <disposition_first_submitted>April 7, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2011</disposition_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Diseases</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 9, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT00006400/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 16, 2006</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT00006400/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>200 patients planned; 233 patients screened; 197 patients eligible for study participation; 193 patients randomized to study treatment; 191 patients initiated study treatment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydroxyurea</title>
          <description>Participants will receive hydroxyurea.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxyurea</title>
          <description>Participants will receive hydroxyurea.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.57" spread="2.60"/>
                    <measurement group_id="B2" value="13.56" spread="2.74"/>
                    <measurement group_id="B3" value="13.56" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Differences of the Change in Qualitative Splenic Function From Baseline</title>
        <description>Primary Endpoint: Spleen function was assessed by uptake of 99mTc sulfur colloid on liver-spleen scan before initiation of treatment (baseline) and 2 years later (exit). The results of each of the two scans were categorized as normal, functional but abnormal, or not functional by a panel of nuclear medicine specialists blinded to treatment assignment. The proportion of patients whose paired scans demonstrated a decline in splenic function was compared in the hydroxyurea versus placebo groups.&#xD;
The change in splenic function from baseline to 2 years was defined as worse if it changed from normal to decreased or absent, or decreased to absent; and not worse if it changed from decreased to decreased, normal to normal, or decreased to normal.</description>
        <time_frame>Before initiation of treatment and at 2 years</time_frame>
        <population>Subjects who had baseline and 2 years splenic function measurements, and had baseline measurement different from absent splenic function. A total of 26 hydroxyurea and 23 placebo subjects had missing data or had absent splenic function at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Participants will receive hydroxyurea.&#xD;
Hydroxyurea: Participants will receive hydroxyurea.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.&#xD;
Placebo: Participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Differences of the Change in Qualitative Splenic Function From Baseline</title>
          <description>Primary Endpoint: Spleen function was assessed by uptake of 99mTc sulfur colloid on liver-spleen scan before initiation of treatment (baseline) and 2 years later (exit). The results of each of the two scans were categorized as normal, functional but abnormal, or not functional by a panel of nuclear medicine specialists blinded to treatment assignment. The proportion of patients whose paired scans demonstrated a decline in splenic function was compared in the hydroxyurea versus placebo groups.&#xD;
The change in splenic function from baseline to 2 years was defined as worse if it changed from normal to decreased or absent, or decreased to absent; and not worse if it changed from decreased to decreased, normal to normal, or decreased to normal.</description>
          <population>Subjects who had baseline and 2 years splenic function measurements, and had baseline measurement different from absent splenic function. A total of 26 hydroxyurea and 23 placebo subjects had missing data or had absent splenic function at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis compared the frequency of worsening spleen function (from normal to decreased or absent, or decreased to absent) and not worsening (from decreased to decreased, normal to normal, or decreased to normal) as measured by splenic uptake on a technetium-99m (99mTc) sulfur colloid liver-spleen scan. Children with missing data or absent spleen function at baseline were excluded from the analysis (26 subjects from hydroxyurea and 23 subjects from placebo group were excluded).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary analysis was done using an intention-to-treat principle.</non_inferiority_desc>
            <p_value>0.21</p_value>
            <p_value_desc>The spleen endpoint was to be tested at an overall alpha = 0.04. Originally there was a second primary outcome to be tested at alpha = 0.01, but this outcome was dropped.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)</title>
        <description>DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded).</description>
        <time_frame>Before initiation of treatment and at 2 years</time_frame>
        <population>Subjects who had baseline and 2 years measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Participants will receive hydroxyurea.&#xD;
Hydroxyurea: Participants will receive hydroxyurea.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.&#xD;
Placebo: Participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)</title>
          <description>DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded).</description>
          <population>Subjects who had baseline and 2 years measurements</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.56" spread="54.67"/>
                    <measurement group_id="O2" value="20.74" spread="51.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to exit as measured by DTPA GFR were compared between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>This was originally a second primary outcome to be tested at alpha = 0.01, but was later dropped from the protocol. We analyzed the available data.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)</title>
        <description>Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
        <time_frame>Before initiation of treatment and at 2 years</time_frame>
        <population>All subjects who had baseline and 2 years GFR calculated using Schwartz formula (0.55× height (cm)/serum creatinine (mg/dL)).</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Participants will receive hydroxyurea.&#xD;
Hydroxyurea: Participants will receive hydroxyurea.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.&#xD;
Placebo: Participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)</title>
          <description>Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
          <population>All subjects who had baseline and 2 years GFR calculated using Schwartz formula (0.55× height (cm)/serum creatinine (mg/dL)).</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.65" spread="76.46"/>
                    <measurement group_id="O2" value="33.36" spread="95.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to exit as measured by GFR (calculated using Shwartz formula) were compared between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>All secondary outcomes were tested at alpha=0.01</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)</title>
        <description>GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
        <time_frame>Before initiation of treatment and at 2 years</time_frame>
        <population>All subjects who had baseline and 2 years GFR calculated using the new Schwartz formula (39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188).</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Participants will receive hydroxyurea.&#xD;
Hydroxyurea: Participants will receive hydroxyurea.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.&#xD;
Placebo: Participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)</title>
          <description>GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis.</description>
          <population>All subjects who had baseline and 2 years GFR calculated using the new Schwartz formula (39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188).</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="20.78"/>
                    <measurement group_id="O2" value="14.33" spread="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in GFR from baseline to exit were compared between treatment groups. GFR was calculated using new Schwartz formula.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>All secondary outcomes were to be tested at alpha = 0.01</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization through study completion, an average of 1.93 years.</time_frame>
      <desc>The CC, NHLBI, and the DSMB continuously monitored the safety of study treatments.&#xD;
A serious adverse event(SAE) was defined as an untoward medical event that is fatal, life threatening, causes/prolongs a hospitalization, or poses a risk of permanent disability, i.e. SAE was defined as one or more of the following:&#xD;
Death&#xD;
Life-threatening events&#xD;
Prolonged hospitalization (greater than 7 days)&#xD;
Splenic sequestration crisis&#xD;
Stroke, TIA&#xD;
Acute chest syndrome&#xD;
ICU admissions</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydroxyurea</title>
          <description>Participants were to receive hydroxyurea.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants were to receive placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenic Sequestration</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Acute chest syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>APLASTIC CRISIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>anemia (Hgb 6.3 - given PRBC transfusion)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>FEVER &gt; 101.5°F(38.4°C)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SEPSIS OR MENINGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Streptococcus pneumonieae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Acute chest syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Possible Accidental Hydroxyurea overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL TCD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>STROKE, WITH NEUROLOGIC DEFICIT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>encephalopathy (indeterminate etiology)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>severe obstructive sleep apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" events="105" subjects_affected="32" subjects_at_risk="96"/>
                <counts group_id="E2" events="84" subjects_affected="35" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" events="35" subjects_affected="15" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" events="65" subjects_affected="33" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER &gt;101.5 F (38.4 C)</sub_title>
                <counts group_id="E1" events="231" subjects_affected="75" subjects_at_risk="96"/>
                <counts group_id="E2" events="272" subjects_affected="82" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="131" subjects_affected="50" subjects_at_risk="96"/>
                <counts group_id="E2" events="268" subjects_affected="62" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Low Grade Fever (&lt;101.5)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="298" subjects_affected="83" subjects_at_risk="96"/>
                <counts group_id="E2" events="326" subjects_affected="77" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Viral Syndrome</sub_title>
                <counts group_id="E1" events="69" subjects_affected="46" subjects_at_risk="96"/>
                <counts group_id="E2" events="80" subjects_affected="46" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="80" subjects_affected="38" subjects_at_risk="96"/>
                <counts group_id="E2" events="103" subjects_affected="48" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="96"/>
                <counts group_id="E2" events="47" subjects_affected="31" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION, FUNGAL</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION, BACTERIAL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Insect Bites</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" events="49" subjects_affected="27" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>DACTYLITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" events="123" subjects_affected="43" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Viral Syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Reactive Airway Disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>RHINORRHEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN INFECTION, FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" events="43" subjects_affected="29" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Diaper DERMATITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Miller</name_or_title>
      <organization>New England Research Institutes, Inc</organization>
      <phone>617-972-3197</phone>
      <email>JMiller@healthcore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

